Studies using different timing of Flt3L treatment demonstrated that DCs can either ameliorate type 1 diabetes when given early in life or increase disease severity if Flt3L is given at later time-points when pre-existing autoimmune T cells are present (74). Here, FLT3LG is linked to type 1 diabetes mellitus.